Mounjaro (Tirzepatide) Injection Site Reactions: Diet Protocols That Help

Does any diet change injection site reactions with Mounjaro?

The Mounjaro label gives no dietary instruction for these reactions; diet and exercise appear in the indication as the adjunct to glycemic control [1]. The tirzepatide trial analyses report injection site reactions by drug exposure and antibody status, not by diet [2].

What the Mounjaro label reports

In the label's pool of placebo-controlled adult trials, injection site reactions were reported in 3.2% of Mounjaro-treated patients versus 0.4% of placebo-treated patients. They are not in the label's table of reactions reported by at least 5% of treated adults, which lists nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain [1].

One analysis of seven phase 3 trials, covering 5,025 tirzepatide-treated adults with type 2 diabetes, found treatment-emergent anti-drug antibodies in 51.1%. Antibody-positive patients reported more hypersensitivity and injection site reactions than antibody-negative patients, but most events were nonserious and nonsevere, and antibody status did not change the drug's pharmacokinetics or efficacy [2]. The label gives 4.6% (119 of 2,570) of antibody-positive versus 0.7% (18 of 2,455) of antibody-negative adults for injection site reactions [1].

What the label says about injecting

• The label instructs injecting subcutaneously in the abdomen or thigh, or having another person inject in the back of the upper arm, and rotating injection sites with each dose [1].
• The label says to administer once weekly, at any time of day, with or without meals [1].
• Exposure to tirzepatide is similar whether the dose goes into the abdomen, thigh or upper arm [1].
• The label says the solution should appear clear and colorless to slightly yellow, and says not to use it if particulate matter or discoloration is seen [1].

When a local reaction is more than local

The Mounjaro label lists serious hypersensitivity reactions, including anaphylaxis and angioedema, and says to discontinue the drug, treat promptly per standard of care and monitor until signs and symptoms resolve if one is suspected [1]. A known serious hypersensitivity to tirzepatide or to any excipient in Mounjaro is a contraindication [1].